Hygieia

Hygieia provides insulin therapy for patients with type 2 diabetes using AI. The company’s flagship product, the d-Nav Insulin Management program, is the first FDA-cleared therapy that automates real-time insulin dose recommendations. The d-Nav technology interprets data and initiates insulin management independently, enabling more frequent and optimal dose adjustments to better manage glucose levels. Alongside the app for dosing, d-Nav users receive support from a team of expert clinicians who review patient data and maintain frequent communication.The company claims that nearly 90% of people using d-Nav report lower A1C in just three months without increasing the risk for hypoglycemia.

Key customers and partnerships

As of January 2024, d-Nav is available through Hygieia's clinic in Michigan or through their endocrinologist clinical partners in select states.

Further, in January 2024, Hygieia announced a partnership with TempraMed, a manufacturer of advanced temperature-based insulin storage solutions.

Funding and financials

In May 2023, the company raised USD 22 million in its extended Series B funding round led by Firstime Ventures, with additional investment from two strategic partners. The funds were used to expand product reach to insulin users by entering new markets across the US.